Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline small index

Blepharitis: full-pipeline trial registry

1 of 7 indexed Blepharitis trials are currently recruiting.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 1 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Blepharitis: 7 US clinical trials tracked, 1 recruiting.

Blepharitis is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is John, George, M.D., running 1 of these trials.

Enrollment posture brief

Registry condition blepharitis

OPEN 1 | RECR 14% | LATE 3 | EARLY 2 | RANK #2497 | SPON 1

Nearest open-share peer: Adverse Drug Events (14% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Acute Myelogenous Leukemia42.9%Acne Scars28.6%Blepharitis (this)14%
Open-enrollment share among volume-matched conditions near Blepharitis

Blepharitis lists 1 open slots (14% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Blepharitis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Blepharitis is recruiting below its size-band peers.

    1 of 7 indexed trials (14.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Blepharitis trials is spread across many organizations.

    John, George, M.D. accounts for 1 of 7 trials (14.3%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Most Blepharitis trials plan to enrol fewer than 100 people.

    Median target enrolment is 36 among the 7 trials that report a genuine target (sentinel values excluded). 6 of those (85.7%) plan for fewer than 100 participants.

  4. Blepharitis research is mostly interventional.

    7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 22Phase 31Phase 42

Phase Distribution

PhaseTrial count
Phase 2 2
Phase 3 1
Phase 4 2

Top Sponsors

Named interventions

Most-linked intervention names on Blepharitis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

COL-101 (doxycycline, USP) capsules Drug
1 trials
AzaSite® Drug
1 trials
Azasite Drug
1 trials
Tobradex ST Drug
1 trials
Besifloxocin Drug
1 trials
Corneal Epithelial Stem Cell Transplant Other
1 trials
Vehicle of TP-03 Drug
1 trials
Ocusoft Lid Scrub Original Foaming Eyelid Cleanser Other
1 trials

US sites by state

Facility locations filed on Blepharitis trials. A trial with sites in several states counts in each.

Kentucky 3 trials
Massachusetts 2 trials
Utah 1 trials
Texas 1 trials
Pennsylvania 1 trials
Oklahoma 1 trials
New York 1 trials
North Carolina 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Blepharitis page

7 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Blepharitis condition card totals 7 registered trials; most-linked intervention COL-101 (doxycycline, USP) capsules; top US site state Kentucky. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.